In addition, studies on human renal cell carcinoma samples have highlighted the therapeutic potential of CTSB in renal cell carcinoma, and the combined inhibition of the vascular endothelial growth factor and CTSB pathways has become a new treatment strategy for patients with metastatic renal cell carcinoma (47). The gene discussed is VEGFA; the disease is renal cell carcinoma.